Oncopeptides AB (publ) (ONCO.ST) Research

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.

Market snapshot

Symbol
ONCO.ST
Price
$1.63
Day change
-0.55%
Market cap
$369.5M
P/E ratio
-1.73x
52-week range
1.255-6.96
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BICO Group AB (publ) (BICO.ST)
  • Cantargia AB (publ) (CANTA.ST)
  • Diamyd Medical AB (publ) (DMYD-B.ST)
  • Genovis AB (publ.) (GENO.ST)
  • Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
  • I-Tech AB (ITECH.ST)
  • Orexo AB (publ) (ORX.ST)
  • Senzime AB (publ) (SEZI.ST)

Open Oncopeptides AB (publ) (ONCO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.